clinically and microbiologically defined infections

Antibiotic Treatment of Febrile Neutropenia in Patients with Acute Leukemia

ANTINEOPLASTIC THERAPY COMPLICATIONS , , , , , ,

VA Okhmat, GA Klyasova, EN Parovichnikova, VV Troitskaya, EO Gribanova, VG Savchenko

National Medical Hematology Research Center, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167

For correspondence: Vladimir Aleksandrovich Okhmat, PhD, 4 Novyi Zykovskii pr-d, Moscow, Russian Federation, 125167; Tel.: +7(495)614-92-72; e-mail: okhmatvladimir@mail.ru

For citation: Okhmat VA, Klyasova GA, Parovichnikova EN, et al. Antibiotic Treatment of Febrile Neutropenia in Patients with Acute Leukemia. Clinical oncohematology. 2018;11(1):100-9.

DOI: 10.21320/2500-2139-2018-11-1-100-109

ABSTRACT

Aim. To estimate the efficacy of antibiotic treatment of febrile neutropenia in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).

Materials & Methods. The prospective study (2013 to 2015) included 66 AML and 44 ALL patients receiving 480 chemotherapy cycles within the period of 6 months.

Results. Febrile neutropenia was registered during 242 (50 %) chemotherapy cycles occurring more frequently in AML than in ALL patients (93 % vs. 18 %, p < 0.0001). In AML patients infections were more common during induction and consolidation (98 and 89 %) phases compared to ALL patients who most commonly had infection during induction phase (55 %). Compared to ALL patients, AML patients had lower recovery rates after first-line antibiotic monotherapy (24 % vs. 57 %, p < 0.0001), compared to combination therapy (37 % vs. 18 %, p = 0.01). The use of beta-lactam antibiotics in ALL patients was associated with lower recovery rates during the induction phase compared to consolidation phase (47 % vs. 72 %, p = 0.0004). In cases of granulocytopaenia longer that 14 days the clinical recovery rate with administration of the first-line antibiotics and carbapenems accounted for 23–24 % compared to 47 % with other antimicrobials, more commonly with antifungal (21 %) administration. In patients with fever of unknown origin the monotherapy with first-line antibiotics proved to be successful (45 %). In patients with clinically and microbiologically defined infections the best results were achieved by the combined treatment with the beta-lactam antibiotics and other drugs (43 %).

Conclusion. Antibiotic escalation has proved to be the optimal strategy in treatment of ALL patients and in cases of fever of unknown origin. The efficacy of the beta-lactam antibiotic monotherapy was lower in AML patients during the induction phase as well as in cases of continuous neutropenia (> 14 days) and clinically and microbiologically diagnosed infections. The adding of other antimicrobial administration resulted in the recovery in 37–48 % of cases.

Keywords: acute leukemia, AML, ALL, febrile neutropenia, fever of unknown origin, clinically and microbiologically defined infections, antibiotics.

Received: July 2, 2017

Accepted: October 20, 2017

Read in PDF 

REFERENCES

  1. Паровичникова Е.Н., Троицкая В.В., Клясова Г.А. и др. Лечение больных острыми миелоидными лейкозами по протоколу российского многоцентрового рандомизированного исследования ОМЛ-01.10: результаты координационного центра. Терапевтический архив. 2014;86(7):14–23. [Parovichnikova EN, Troitskaya VV, Klyasova GA, et al. Treating patients with acute myeloid leukemias (AML) according to the protocol of the AML-01.10 Russian multicenter randomized trial: The coordinating center’s results. Terapevticheskii arkhiv. 2014;86(7):14–23. (In Russ)]
  2. Паровичникова Е.Н., Клясова Г.А., Исаев В.Г. и др. Первые итоги терапии Ph-негативных острых лимфобластных лейкозов взрослых по протоколу Научно-исследовательской группы гематологических центров России ОЛЛ-2009. Терапевтический архив. 2011;83(7):11–7. [Parovichnikova EN, Klyasova GA, Isaev VG, et al. Pilot results of therapy of adult Ph-negative acute lymphoblastic leukemia according to the protocol of Research Group of Russian Hematological Centers ALL-2009. Terapevticheskii arkhiv. 2011;83(7):11–7. (In Russ)]
  3. Войцеховский В.В., Груздова А.В., Филатова Е.А. и др. Анализ инфекционных осложнений гемобластозов в Амурской области.Бюллетень физиологии и патологии дыхания. 2012;46:64–8. [Voitsekhovskii VV, Gruzdova AV, Filatova EA, et al. The analysis of infectious complications of hemoblastosis in the Amur region. Byulleten’ fiziologii i patologii dykhaniya. 2012;46:64–8. (In Russ)]
  4. Mikulska M, Viscoli C, Orasch C, et al. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect. 2013;68(4):321–31. doi: 10.1016/j.jinf.2013.12.006.
  5. Клясова Г.А. Антимикробная терапия. В кн.: Программное лечение заболеваний системы крови: сборник алгоритмов диагностики и протоколов лечения заболеваний системы крови. Под ред. В.Г. Савченко. М.: Практика, 2012. С. 827–54. [Klyasova GA. Antimicrobial therapy. In: Savchenko VG, ed. Programmnoe lechenie zabolevanii sistemy krovi: sbornik algoritmov diagnostiki i protokolov lecheniya zabolevanii sistemy krovi. (Program treatment of blood system diseases.) Moscow: Praktika Publ.; 2012. pp. 829–53. (In Russ)]
  6. Averbuch D, Cordonnier C, Livermore DM, et al. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: Guidelines of the 4th European conference on Infections in Leukemia (ECIL-4, 2011). Haematologica. 2013;98(12):1836–47. doi: 10.3324/haematol.2013.091330.
  7. Tumbarello M, Sanguinetti M, Montuori E, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother. 2007;51(6):1987–94. doi:10.1128/AAC.01509–06.
  8. Савченко В.Г., Паровичникова Е.Н., Афанасьев Б.В. и др. Национальные клинические рекомендации по диагностике и лечению острых миелоидных лейкозов взрослых. Гематология и трансфузиология. 2014;59(S2):2–29. [Savchenko VG, Parovichnikova EN, Afanas’ev BV, et al. National clinical guidelines for the diagnosis and treatment of acute myeloid leukemia in adults. Gematologiya i transfusiologiya. 2014;59(S2):2–29. (In Russ)]
  9. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–55.
  10. Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica. 2013;98(12):1826–35. doi: 10.3324/haematol.2013.091025.
  11. Клясова Г.А., Коробова А.Г., Фролова И.Н. и др. Детекция энтеробактерий с продукцией β-лактамаз расширенного спектра у больных острыми миелоидными лейкозами и лимфомами при поступлении в стационар. Гематология и трансфузиология. 2016;61(1):25–32. doi: 10.18821/0234-5730-2016-61-1-25-32. [Klyasova GA, Korobova AG, Frolova IN, et al. Detection of extended-spectrum β-lactamase producing Enterobacteriaceae (ESBL-E) among patients with acute myeloid leukemia and lymphoma upon admission to hospital. Gematologiya i transfusiologiya. 2016;61(1):25–32. doi: 10.18821/0234-5730-2016-61-1-25-32. (In Russ)]
  12. Охмат В.А., Клясова Г.А., Коробова А.Г. и др. Следует ли назначать карбапенемы всем больным с фебрильной нейтропенией и колонизацией энтеробактериями с продукцией β-лактамаз расширенного спектра? Онкогематология. 2016;11(3):49–57. doi: 10.17650/1818-8346-2016-11-3-49-57. [Okhmat VA, Klyasova GA, Korobova AG. Should to all patients with febrile neutropenia and colonization with extended-spectrum β-lactamase-producing Enterobacteriaceae carbapenems be appointed? Oncohematology. 2016;11(3):49–57. doi: 10.17650/1818-8346-2016-11-3-49-57. (In Russ)]
  13. Aynioglu Mujeeb VR, Jambunathan P, Tyagi A. Comparison of Efficacy of Piperacillin/Tazobactam Vs Cefoperazone/Sulbactam as Empirical Therapy in Patients with Febrile Neutropenia. Ann Int Med Dent Res. 2017;3(2):51–5. doi: 10.21276/aimdr.2017.3.2.me12.
  14. Demir HA, Kutluk T, Ceyhan M, et al. Comparison of sulbactam-cefoperazone with carbapenems as empirical monotherapy for febrile neutropenic children with lymphoma and solid tumors. Pediatr Hematol Oncol. 2011;28(4):299–310. doi: 3109/08880018.2011.552937.
  15. Jing Y, Li J, Yuan L, et al. Piperacillin‐tazobactam vs. imipenem‐cilastatin as empirical therapy in hematopoietic stem cell transplantation recipients with febrile neutropenia. Clin Transplant. 2016;30(3):263–9. doi: 1111/ctr.12685.
  16. Охмат В.А., Клясова Г.А., Паровичникова Е.Н. и др. Спектр и этиология инфекционных осложнений у больных острыми миелоидными лейкозами на этапах индукции и консолидации ремиссии. Гематология и трансфузиология. 2017;62(1):9–15. [Okhmat VA, Klyasova GA, Parovichnikova EN, et al. Spectrum and epidemiology of infection complications in patients with acute myeloid leukemia during induction and consolidation chemotherapy. Gematologiya i transfusiologiya. 2017;62(1):9–15. (In Russ)]
  17. Pizzo PA. After empiric therapy: what to do until the granulocyte comes back. Rev Infect Dis. 1987;9(1):214–9. doi: 1093/clinids/9.1.214.
  18. Link H, Maschmeyer G, Meyer PF, et al. Interventional antimicrobial therapy in febrile neutropenic patients. Ann Hematol. 1994;69(5):231–43. doi: 1007/BF01700277.
  19. Viscoli C, Cometta A, Kern WV, et al. Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients. Clin Microbiol Infect. 2006;12(3):212–6. doi: 10.1111/j.1469-0691.2005.01297.x.